13F-HR filed by Venrock Adviser, LLC
Venrock Adviser, LLC filed this 13F-HR for the quarter ended 2020-12-31, filed 2021-02-12, with 25 holding rows worth $680,147,000.
- Accession
- 0001104659-21-021905
- Filer
- CIK 1615982
- Filed
- 2021-02-12
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q4 2020
A holdings report, 25 entries on the cover page, a total value of $680,147,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $680,145,000 with VALUE read as thousands by filing date, 13F file number 028-20281. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| CONSTELLATION PHARMACEUTICALS INC. | 210373106 | Common Stock | 4,016,873 | $115,686,000 | thousands by filing date | |
| OLEMA PHARMACEUTICALS INC | 68062P106 | COM | 1,536,193 | $73,860,000 | thousands by filing date | |
| TRILLIUM THERAPEUTICS INC COM NEW | 89620X506 | Stock | 4,040,000 | $59,428,000 | thousands by filing date | |
| KINNATE BIOPHARMA INC | 49705R105 | COM | 1,473,014 | $58,596,000 | thousands by filing date | |
| ATHIRA PHARMA INC | 04746L104 | COM | 1,691,623 | $57,938,000 | thousands by filing date | |
| ALTIMMUNE INC | 02155H200 | COM NEW | 4,500,000 | $50,760,000 | thousands by filing date | |
| KEROS THERAPEUTICS INC COM | 492327101 | Stock | 672,306 | $47,424,000 | thousands by filing date | |
| MARINUS PHARMACEUTICALS INC | 56854Q200 | COM NEW | 2,588,941 | $31,585,000 | thousands by filing date | |
| SYNDAX PHARMACEUTICALS INC | 87164F105 | COM | 1,115,255 | $24,803,000 | thousands by filing date | |
| RELMADA THERAPEUTICS INC | 75955J402 | COMMON STOCK | 668,440 | $21,437,000 | thousands by filing date | |
| KURA ONCOLOGY INC COM | 50127T109 | Stock | 575,000 | $18,780,000 | thousands by filing date | |
| VISTAGEN THERAPEUTICS INC | 92840H202 | COM | 9,360,000 | $18,158,000 | thousands by filing date | |
| CELLDEX THERAPEUTICS INC NEW | 15117B202 | COM NEW | 800,000 | $14,016,000 | thousands by filing date | |
| SURFACE ONCOLOGY INC | 86877M209 | COM | 1,442,895 | $13,332,000 | thousands by filing date | |
| ACLARIS THERAPEUTICS INC COM | 00461U105 | Stock | 1,954,932 | $12,648,000 | thousands by filing date | |
| COGENT BIOSCIENCES INC | 19240Q201 | COM | 1,088,817 | $12,227,000 | thousands by filing date | |
| ALIGOS THERAPEUTICS INC COM NEW | 01626L105 | Stock | 404,906 | $11,196,000 | thousands by filing date | |
| GALERA THERAPEUTICS EQUICLASS EQUITY | 36338D108 | COMMON STOCK | 917,860 | $9,390,000 | thousands by filing date | |
| ARS PHARMACEUTICALS INC | 82835W108 | COM | 150,000 | $6,951,000 | thousands by filing date | |
| BCTG ACQUISITION CORP | 05492W103 | COM | 500,000 | $5,720,000 | thousands by filing date | |
| METACRINE INC | 59101E103 | COM | 693,673 | $5,452,000 | thousands by filing date | |
| FIVE PRIME THERAPEUTICS INC. | 33830X104 | Common Stock | 245,122 | $4,170,000 | thousands by filing date | |
| BIOATLA INC | 09077B104 | COM | 100,000 | $3,401,000 | thousands by filing date | |
| TAYSHA GENE THERAPIES INC | 877619106 | COMMON STOCK | 107,982 | $2,866,000 | thousands by filing date | |
| VIRIDIAN THERAPEUTICS INC | 92790C104 | COM | 19,495 | $321,000 | thousands by filing date |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001104659-21-021905 | this filing | 2021-02-12 | acceptance time not in the bulk data set |